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Background: Adult congenital heart disease (ACHD) patients are often described as having a chronic heart failure (HF) syndrome. It is well known 
that acquired HF patients have serum biomarkers that may provide diagnostic and prognostic data. We sought to characterize these biomarkers in 
ACHD patients and correlate them with clinical severity.
Methods: Serum samples were collected from 2007 to 2011 in 77 clinic patients with with at least moderately complex ACHD (43 male; mean 
age 32.8 ±8.7 years). Immunoassays analyzed 32 biomarkers associated with cardiac, renal, liver, brain, or inflammatory derangements. Also, 
comparisons of functional status by New York Heart Association (NYHA) Class and maximal oxygen consumption (MVO2) on cardiopulmonary 
exercise testing to serum biomarkers were performed using one-way analysis of variance (ANOVA) with a 95% confidence interval.
Results: BNP, CRP, TNF-_, P-selectin, MMP-9, adrenomedullin, endothelin, and cystatin-C were all markedly increased in our cohort. Patients with 
advanced HF also displayed particularly elevated biomarkers. NYHA Class III and IV patients had higher epoetin, GFAP, IL-6, and norepinephrine than 
NYHA Classes I and II. Patients with a decreased MVO2 had higher GGT-1, PICP, Uric Acid, and _ -2-macroglobulin compared to those with a normal 
MVO2. Patients with a BNP ≥ 200 pg/mL displayed a significant increase in apelin-13, CK-BB, GGT-1, IL-2, IL-6, MYL-1, PICP, TnT, and UCHL1 when 
compared with a BNP < 200 pg/mL.
Conclusions: Our cohort had a marked elevation of biomarkers that are specific for inflammation, extracellular matrix remodeling, and impaired 
renal function. Markers of clinical deterioration, including advanced NYHA Class, lower MVO2, and higher serum BNP were significantly correlated 
with elevated biomarkers related to cardiac, renal, liver, brain, and systemic inflammatory disease, which suggests evidence of chronic systemic 
disease and multi-organ impairment in this group.
